Low-birthweight children and those born small for their gestational age (SGA) are likely to be salt sensitive, according to study findings published online Aug. 11 in Hypertension.
Low-birthweight children and those born small for their gestational age (SGA) are likely to be salt sensitive, according to study findings published online Aug. 11 in Hypertension.
Giacomo D. Simonetti, MD, and colleagues from Bern University Hospital and University of Bern in Switzerland measured the glomerular filtration rate and salt sensitivity (a mean blood pressure increase of 3 mm Hg or more over 24 hours on a high-salt diet compared with a controlled-salt diet) in 50 white children (mean age 11.3 years). Of these, 35 were of low birthweight and 15 were of normal birthweight, and 25 were SGA and 25 were appropriate for gestational age.
The researchers found that the low-birthweight children had significantly higher baseline blood pressure, a significantly lower glomerular filtration rate, and significantly reduced kidney length and volume compared with children of normal birthweight. In addition, 37% of low-birthweight children and 47% of SGA children had salt sensitivity. There was a significant inverse correlation between salt sensitivity and kidney length but not glomerular filtration rate, the report indicates.
“We conclude that a reduced renal mass in growth-restricted children poses a risk for a lower renal function and for increased salt sensitivity,” Simonetti and colleagues write. “Whether the changes in renal growth are causative or are the consequence of the same abnormal ‘fetal programming’ awaits clarification.”
Simonetti GD, Raio L Surbek D, et al. Salt sensitivity of children with low birthweight.
Hypertension
. 2008;52:625-630
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More